Detection of type2 biomarkers for response in COPD

Area of Science:

• Pulmonology
• Biomarkers
• Inflammatory Diseases

Background:

• Chronic obstructive pulmonary disease (COPD) is a complex inflammatory lung condition.
• Identifying patients who benefit from anti-inflammatory treatments like inhaled corticosteroids (ICS) is crucial.
• Predictive biomarkers for ICS response in COPD are needed.

Purpose of the Study:

• To assess inflammatory biomarkers for predicting ICS treatment response in COPD.
• To correlate biomarker levels with changes in COPD symptoms and lung function.

Main Methods:

• Prospective study of 43 symptomatic COPD patients receiving ciclesonide (ICS) plus bronchodilators.
• Measured blood eosinophils, exhaled nitric oxide (FeNO), alveolar nitric oxide (Calv), IgE, and atopy.
• Assessed changes in COPD Assessment Test (CAT) scores and FEV1 at 12 weeks.

Main Results:

• FeNO demonstrated high predictive value (AUC 0.92) for improvements in CAT score and FEV1.
• Specific FeNO cutoffs identified high likelihood (35 ppb) and low likelihood (20 ppb) of response.
• Baseline FeNO strongly correlated with improvements in FEV1 and CAT scores (p < 0.0001).

Conclusions:

• Exhaled nitric oxide (FeNO) is a valuable biomarker for predicting ICS response in COPD.
• FeNO can identify patients likely to improve symptomatically and in lung function with steroid therapy.
• This biomarker aids in personalized treatment strategies for symptomatic COPD.